2-nitro-3-methylimidazo(4,5-f)quinoline
structure given in first source
Also Known As:
IQ(NO2); nitro-IQ
Networked: 3
relevant articles (0 outcomes,
0 trials/studies)
Bio-Agent Context: Research Results
Related Diseases
1. | Chromosome Aberrations (Chromosome Abnormalities)
02/01/1994
- " Multiple treatment with IQ or nitro-IQ induced significant chromosome aberrations time- and dose-dependently, the maximum frequency of chromosome aberrations in metaphase cells being 39 and 33% respectively, while that in controls was 1.1%. " 02/01/1994
- " Cumulative effects of chromosome aberrations and sister chromatid exchanges (SCEs) were studied in hepatocytes of F344 rats exposed in vivo to 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) at doses of 12.5, 25 or 50 mg/kg body wt/day or 2-nitro-3-methylimidazo[4,5-f]quinoline (nitro-IQ) at doses of 12.5, 25 or 50 mg/kg body wt/day. " 11/01/1991
- " Intraperitoneal injections of Trp-P-1, Glu-P-1, MeIQx, IQ and nitro-IQ resulted in chromosome aberrations in up to 16% of the metaphase cells and SCEs at up to 0.9 per chromosome, while injections of Trp-P-2 and Glu-P-2 produced SCEs at up to 0.7 and 1.1 per chromosome, respectively. "
|
2. | Carcinogenesis
|
|
Related Drugs and Biologics
Related Therapies and Procedures